Study With Two Coenzyme Q10 Products

Last updated: December 4, 2025
Sponsor: University of Primorska
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Dietary supplement - Experimental product

Dietary supplement - Active comparator

Clinical Study ID

NCT06736366
Q10_2024
  • Ages 50-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The randomized, open-label, two period crossover single-dose bioavailability study with two coenzyme Q10 products

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • subject informed consent form

  • aged between 50 and 65 years old

  • body mass for women 70± 5 kg and for men 85± 5 kg

  • non-smoking

  • healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases

  • absence of any prescribed medication during the study

  • willing to avoid a consumption of any food supplements at least 2 weeks before andduring the study

Exclusion

Exclusion Criteria:

  • cardio-vascular diseases, diabetes, neurodegenerative diseases, gastrointestinaldisorders, pregnancy, breast-feeding

  • intake of any food supplements within two week of the beginning of the study

  • drug or alcohol abuse

Study Design

Total Participants: 25
Treatment Group(s): 2
Primary Treatment: Dietary supplement - Experimental product
Phase:
Study Start date:
December 05, 2024
Estimated Completion Date:
June 30, 2025

Study Description

The randomized, open-label, two period crossover single-dose bioavailability study with two coenzyme Q10 products will include 35 subjects who will test two different coenzyme Q10 products. Plasma concentration of coenzyme Q10 will be measured.

Connect with a study center

  • University of Primorska, Faculty of Health Sciences

    Izola 3199017, Izola 3199016 6310
    Slovenia

    Site Not Available

  • University of Primorska, Faculty of Health Sciences

    Izola, 6310
    Slovenia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.